In this randomized multicentric phase II study, patients with colorectal carcinoma with resectable hepatic metastasis will be randomized to treatment with dendritic cells or to observation, following conventional treatment with surgery and chemotherapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
58
Vaccination with autologous dendritic cells loaded with autologous tumor antigens
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
RECRUITINGHospital de Navarra
Pamplona, Navarre, Spain
RECRUITINGProgression Free survival
Time frame: Progression free survival at 2 years
Overall survival
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.